MTN-003, or Vaginal and Oral Interventions to Control the Epidemic (VOICE), was a Phase Iib study that tested the safety and effectiveness of two different HIV prevention approaches among 5,029 women in South Africa, Uganda and Zimbabwe: daily use of an ARV tablet (tenofovir or Truvada) or daily use of a vaginal gel (tenofovir gel). The study was conducted from 2009 to 2012. Results, first reported in 2013, found all three products were safe but none was effective, as most participants did not use them daily as recommended. Young, unmarried women were least likely to use study products and the most likely to acquire HIV.

(See also MTN-003B/VOICE B; MTN-003C/VOICE C; and MTN-003D/VOICE D).

Results

Final results of the HIV prevention study VOICE are published in NEJM

04-February-2015
 

VOICE Q&A

4-February-2015

 

Women who took part in VOICE study speak up about why they didn’t use the HIV prevention products being tested

29-October-2014

 

New results from VOICE associates tenofovir gel use with lower HSV-2 risk in women

28-October-2014

 

Secondary Analysis of VOICE: Injectable Contraception and HIV Risk Q&A

31-March-2014

 

First Comparison Between Injectable Contraceptives DMPA and NET-EN Suggests Some Women Using DMPA Were at Higher Risk of Acquiring HIV

4-March-2014

 

Behavioral Measures of Product Use Didn’t Measure Up in VOICE HIV Prevention Trial, Report the Study’s Researchers

4-March-2014

 

Daily HIV Prevention Approaches Didn’t Work for African Women in the VOICE Study

4-March-2013

 

Fact sheet – The VOICE C and VOICE D Social and Behavioral Research Sub-studies: Looking for answers about adherence and the women in VOICE

4-September-2013

 

VOICE Fact Sheet – Understanding the Results of VOICE

4-March-2013

 

NIAID Press Release on VOICE Results

4-March-2013

 

Other Study Milestones

Microbicide Trials Network Statement on Decision to Discontinue Use of Tenofovir Gel in VOICE, a Major HIV Prevention Study in Women

25-November-2011

 

Questions and Answers on Decision to Modify VOICE, Outcome of November 17 DSMB Review

25-November-2011

 

Microbicide Trials Network Statement on Decision to Discontinue Use of Oral Tenofovir Tablets in VOICE, a Major HIV Prevention Study in Women

28-September-2011

 

Questions and Answers on Decision to Modify VOICE, Outcome of September 16 DSMB Review

28-September-2011

 

HIV Prevention Trial Milestone: VOICE Study Completes Enrollment of 5,000 Women

6-June-2011

 

VOICE Study, a major HIV prevention trial for women, is launched in Zimbabwe

16-September-2009

 

NIAID Press Release on start of VOICE

16-September-2009

 

HIV prevention trial of ARV-based strategies to begin next month

20-July-2009

 

VOICE and Related Trials

Questions and Answers about the CDC TDF2 Study and VOICE

14-July-2011

 

VOICE Study will Continue as it Considers What Action to Take After Results of Two Trials

13-July-2011

 

Questions and Answers about Partners PrEP and VOICE

13-July-2011

 

Microbicide Trials Network Statement on the status of VOICE Study following announcement to close the FEM-PrEP trial

18-April-2011

 

Trial shows ARVs can prevent HIV in men who have sex with men, making VOICE Study in women more important than ever

23-November-2010

 

Results of CAPRISA 004 a turning point for HIV prevention, say MTN researchers conducting VOICE

19-July-2010

 

Understanding Resistance

Please note that the information contained in the following materials may have changed since publication.

Drug Resistance and ARV-Based Prevention Fact Sheet

 

Drug Resistance and ARV-Based Prevention Q&A

 

Diagrams:

Video: Drug Resistance and ARV-Based Prevention

 

See Also

MTN-003 (VOICE) Study Protocol

 

MTN-003 (VOICE) Study Page

 

MTN-003 B (VOICE B) Study Protocol

 

MTN-003 C (VOICE C) Study Protocol


MTN-003 D (VOICE D) Study Protocol